Trials / Completed
CompletedNCT00096928
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,846 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.
Conditions
Timeline
- Start date
- 2005-03-01
- Completion
- 2009-10-01
- First posted
- 2004-11-18
- Last updated
- 2015-07-02
Locations
182 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00096928. Inclusion in this directory is not an endorsement.